+ Site Statistics
References:
52,572,879
Abstracts:
28,705,754
PMIDs:
27,750,366
DOIs:
25,464,004
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Effect of pan-histone deacetylase inhibitor panobinostat (LBH589) on CXCR4 levels and signaling and on anti-leukemia activity in combination with CXCR4 antagonists



Effect of pan-histone deacetylase inhibitor panobinostat (LBH589) on CXCR4 levels and signaling and on anti-leukemia activity in combination with CXCR4 antagonists



Journal of Clinical Oncology 26(15_Suppl): 14541-14541



NlmCategory="UNASSIGNED">14541 Background: Bone marrow stroma-derived factor-1 (SDF-1, CXCL12) binds and activates the chemokine receptor CXCR4, which regulates the trafficking and mobilization of normal and leukemic hematopoietic cells. CXCR4 signaling thorough AKT and c-Raf also promotes survival and decreases sensitivity of AML cells to anti-leukemia agents. Both CXCL12 and CXCR4 are overexpressed and confer poor prognosis in AML. Treatment with the CXCR4 antagonist AMD3100 sensitizes AML cells to anti-leukemia drugs. We determined the effect of panobinostat (P) and/or FC-131 (a new generation CXCR4 inverse agonist) on CXCR4 expression and signaling in cultured and primary AML cells. Following treatment of human AML OCI-AML3, HL-60, and Jurkat cells, as well as primary AML cells with P (10 to 50 nM) and/or FC-131 (10 nM) with our without 10 nM of CXCL12, cell surface expression of CXCR4 and apoptosis (Annexin V/PI staining) were determined by flow cytometry. Intracellular protein levels of CXCR4, p-AKT, p-ERK1/2, heat shock protein (hsp) 70 and hsp90 were determined by immunoblot (IB) analyses. Binding of CXCR4 to hsp90 and hsp70, as well as CXCR4 acetylation, were determined by immunoprecipitation (IP)/IB analyses. Treatment with P depleted the intracellular and surface expression of CXCR4 in the presence or absence of CXCL12. P induced acetylation of hsp90 and decreased its binding to CXCR4. P also induced acetylation and increased membrane binding of CXCR4 to hsp70. P promoted degradation of CXCR4 by the proteasome. Treatment with P alone also decreased p-AKT and p-ERK1/2. Co- treatment with P markedly attenuated the phosphorylation (p) of AKT and ERK1/2 induced by CXCL12, casuing apoptosis of up to 50% of cultured and primary AML cells. Co-treatment with P and FC-131 caused greater depletion of CXCR4, p-AKT and p-ERK1/2 levels, and synergistically induced apoptosis of the cultured AML cells (combination indices of < 1.0, utilizing isobologram analysis). CXCR4 is chaperoned by hsp90, and treatment with P depletes CXCR4 levels and signaling in AML cells. The novel combination of FC-131 and P is synergistically active and its in vivo ant-AML efficacy is currently under evaluation. [Table: see text].

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 057707770

Download citation: RISBibTeXText

PMID: 27950012


Related references

Pan-histone deacetylase inhibitor panobinostat depletes CXCR4 levels and signaling and exerts synergistic antimyeloid activity in combination with CXCR4 antagonists. Blood 116(24): 5306-5315, 2011

Pan-histone deacetylase (HDAC) inhibitor LBH589 depletes CXCR4 levels combination with CXCR4 antagonists.. 2007

Cytotoxic activity of the histone deacetylase inhibitor panobinostat (LBH589) in anaplastic thyroid cancer in vitro and in vivo. International Journal of Cancer 130(3): 694-704, 2012

Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor. Cancer ChemoTherapy and Pharmacology 68(3): 805-813, 2011

Influence of a novel histone deacetylase inhibitor panobinostat (LBH589) on the growth of ovarian cancer. Journal of Ovarian Research 9(1): 58, 2017

Inhibition of the proliferation of acquired aromatase inhibitor-resistant breast cancer cells by histone deacetylase inhibitor LBH589 (panobinostat). Breast Cancer Research and Treatment 137(1): 93-107, 2013

The antimelanoma activity of the histone deacetylase inhibitor panobinostat (LBH589) is mediated by direct tumor cytotoxicity and increased tumor immunogenicity. Melanoma Research 23(5): 341-348, 2015

The pan-histone deacetylase inhibitor LBH589 (panobinostat) alters the invasive breast cancer cell phenotype. International Journal of Oncology 44(3): 700-708, 2014

Phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in patients with low or intermediate-1 risk myelodysplastic syndrome. American Journal of Hematology 87(1): 127-129, 2012

The histone deacetylase inhibitor LBH589 (panobinostat) modulates the crosstalk of lymphocytes with Hodgkin lymphoma cell lines. Plos One 8(11): E79502, 2014

Molecular Mechanism of the Cell Death Induced by the Histone Deacetylase Pan Inhibitor LBH589 (Panobinostat) in Wilms Tumor Cells. Plos One 10(7): E0126566, 2016

A phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in pretreated patients with small-cell lung cancer. Journal of Thoracic Oncology 8(8): 1091-1094, 2014

Depletion of HDAC7 and de-repression of Nur77: a mechanism for sensitivity of cutaneous lymphoma (CTCL) cells to pan- histone deacetylase inhibitor Panobinostat (LBH589). Journal of Clinical Oncology 26(15_Suppl): 14542-14542, 2016

Histone deacetylase inhibitors induce CXCR4 mRNA but antagonize CXCR4 migration. Cancer Biology and Therapy 14(2): 175-183, 2013

Effects of Histone Deacetylase Inhibitor Panobinostat (LBH589) on Bone Marrow Mononuclear Cells of Relapsed or Refractory Multiple Myeloma Patients and Its Mechanisms. Medical Science Monitor 23: 5150-5157, 2018